Douglas Reznick is an Oncology physician affiliated with Rocky Mountain Cancer Centers. OpenAlex indexes 5 publications with 261 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1700 S Potomac St
Aurora, CO 800125405
Telephone
303-418-7600Provider last certified this registry record 17 Feb 2025.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202514 payments$20,493openpaymentsdata.cms.gov ↗
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year20259 payments
- Ethicon Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
40.1%Erythropoiesis-stimulating Agent20.7%Darbepoetin alfa100%Part B, office-administered≥11 patientsParenteral Iron Replacement15.2%Iron sucrose100%Part B, office-administered≥17 patients+ 4 more classes in this area
Cancer & immunology
28.3%PD-1 inhibitor27.4%Pembrolizumab100%Part B, office-administered≥15 patientsPlatinum-based Drug0.7%Carboplatin100%Part B, office-administered≥17 patients+ 2 more classes in this area
Metabolism & gastrointestinal
17.8%Other antiemetics13%Fosaprepitant100%Part B, office-administered≥19 patientsSerotonin-3 Receptor Antagonist3.6%Palonosetron hcl57%Granisetron hydrochloride42%Ondansetron Hcl1%Part D + Part B≥34 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase II multicenter trial of docetaxel+oxaliplatin in stage IV gastroesophageal and/or stomach cancer
Journal of Clinical Oncology
2006
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”